Free Trial

Royalty Pharma (RPRX) Competitors

Royalty Pharma logo
$36.19 +0.31 (+0.86%)
Closing price 04:00 PM Eastern
Extended Trading
$36.20 +0.01 (+0.03%)
As of 06:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

RPRX vs. ZTS, CORT, JAZZ, PRGO, SUPN, PCRX, OMER, ASMB, NKTR, and CPIX

Should you be buying Royalty Pharma stock or one of its competitors? The main competitors of Royalty Pharma include Zoetis (ZTS), Corcept Therapeutics (CORT), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Supernus Pharmaceuticals (SUPN), Pacira BioSciences (PCRX), Omeros (OMER), Assembly Biosciences (ASMB), Nektar Therapeutics (NKTR), and Cumberland Pharmaceuticals (CPIX). These companies are all part of the "pharmaceuticals" industry.

Royalty Pharma vs. Its Competitors

Royalty Pharma (NASDAQ:RPRX) and Zoetis (NYSE:ZTS) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

54.4% of Royalty Pharma shares are owned by institutional investors. Comparatively, 92.8% of Zoetis shares are owned by institutional investors. 18.9% of Royalty Pharma shares are owned by insiders. Comparatively, 0.2% of Zoetis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Zoetis had 12 more articles in the media than Royalty Pharma. MarketBeat recorded 31 mentions for Zoetis and 19 mentions for Royalty Pharma. Zoetis' average media sentiment score of 1.47 beat Royalty Pharma's score of 1.15 indicating that Zoetis is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Royalty Pharma
11 Very Positive mention(s)
5 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Zoetis
26 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Royalty Pharma has a beta of 0.5, meaning that its share price is 50% less volatile than the S&P 500. Comparatively, Zoetis has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500.

Royalty Pharma pays an annual dividend of $0.88 per share and has a dividend yield of 2.4%. Zoetis pays an annual dividend of $2.00 per share and has a dividend yield of 1.3%. Royalty Pharma pays out 47.6% of its earnings in the form of a dividend. Zoetis pays out 35.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Royalty Pharma has increased its dividend for 5 consecutive years and Zoetis has increased its dividend for 14 consecutive years.

Royalty Pharma presently has a consensus target price of $47.33, indicating a potential upside of 30.79%. Zoetis has a consensus target price of $212.13, indicating a potential upside of 33.34%. Given Zoetis' higher possible upside, analysts plainly believe Zoetis is more favorable than Royalty Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Royalty Pharma
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
3.25
Zoetis
0 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
2 Strong Buy rating(s)
3.00

Zoetis has higher revenue and earnings than Royalty Pharma. Royalty Pharma is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Royalty Pharma$2.26B8.99$858.98M$1.8519.56
Zoetis$9.26B7.65$2.49B$5.5728.56

Royalty Pharma has a net margin of 48.23% compared to Zoetis' net margin of 27.12%. Zoetis' return on equity of 55.48% beat Royalty Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Royalty Pharma48.23% 24.71% 13.87%
Zoetis 27.12%55.48%19.14%

Summary

Zoetis beats Royalty Pharma on 15 of the 20 factors compared between the two stocks.

Get Royalty Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for RPRX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RPRX vs. The Competition

MetricRoyalty PharmaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$20.17B$2.88B$5.54B$8.87B
Dividend Yield2.45%2.64%5.39%4.10%
P/E Ratio19.5621.3126.1719.90
Price / Sales8.99278.47414.67113.66
Price / Cash8.5541.4736.1356.90
Price / Book2.067.518.055.38
Net Income$858.98M-$55.05M$3.15B$248.50M
7 Day Performance0.78%2.45%1.85%2.97%
1 Month Performance8.81%7.33%4.81%6.02%
1 Year Performance39.84%5.38%34.86%20.39%

Royalty Pharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RPRX
Royalty Pharma
4.9145 of 5 stars
$36.19
+0.9%
$47.33
+30.8%
+37.0%$20.17B$2.26B19.5680Positive News
Analyst Downgrade
ZTS
Zoetis
4.8304 of 5 stars
$157.51
+0.2%
$212.13
+34.7%
-7.8%$70.12B$9.29B28.2813,800Positive News
CORT
Corcept Therapeutics
4.7142 of 5 stars
$74.28
+4.1%
$138.25
+86.1%
+112.2%$7.88B$675.04M64.03300Positive News
JAZZ
Jazz Pharmaceuticals
4.9285 of 5 stars
$106.76
-0.7%
$184.00
+72.3%
+2.8%$6.46B$4.07B14.232,800Positive News
PRGO
Perrigo
4.9506 of 5 stars
$26.43
-0.3%
$33.00
+24.9%
+4.3%$3.63B$4.34B-20.188,379News Coverage
SUPN
Supernus Pharmaceuticals
2.3105 of 5 stars
$31.99
-0.9%
$36.00
+12.5%
+19.8%$1.79B$661.82M28.82580
PCRX
Pacira BioSciences
3.5455 of 5 stars
$24.74
+2.1%
$26.44
+6.9%
-18.3%$1.15B$700.97M-10.85720Positive News
OMER
Omeros
3.7002 of 5 stars
$3.19
-0.6%
$18.00
+464.3%
-24.8%$186.90MN/A-1.20210Positive News
Analyst Forecast
ASMB
Assembly Biosciences
3.544 of 5 stars
$17.10
-1.7%
$33.00
+93.0%
+33.9%$130.64M$28.52M-2.74100News Coverage
High Trading Volume
NKTR
Nektar Therapeutics
4.6143 of 5 stars
$9.54
+12.1%
$67.50
+607.5%
+34.4%$118.39M$98.43M-0.99220Analyst Revision
Gap Down
High Trading Volume
CPIX
Cumberland Pharmaceuticals
0.5338 of 5 stars
$3.93
-9.7%
N/A+133.4%$58.79M$37.87M-15.7280Gap Down

Related Companies and Tools


This page (NASDAQ:RPRX) was last updated on 7/2/2025 by MarketBeat.com Staff
From Our Partners